Editorial
|
|
|
|
|
Calling initial assessments into question
|
|
|
|
Marketing Authorisations
|
|
|
|
|
No more effective than other gliptins, but a high potential for drug interactions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inadequately assessed, no proven advantages
|
|
|
|
|
|
|
|
|
|
Promising, but more data needed
|
|
|
|
Adverse Effects
|
|
|
|
|
Mostly corticosteroids, even after local or inhaled treatment
|
|
|
|
|
|
|
|
|
|
Combined contraceptives: levonorgestrel and norethisterone are safer
|
|
|
|
|
|
|
|
|
|
Pulmonary arterial hypertension and valve damage
|
|
|
|
|
|
Reviews
|
|
|
|
|
Fluorouracil + folinic acid for node-positive, non-metastatic disease
|
|
|
|
|
|
|
|
|
|
|
|
ACE inhibitors, angiotensin II receptor blockers and aliskiren must be avoided
|
|
|
|
|
|
Outlook
|
|
|
|
|
Patients need access to balanced information
|
|
|
|
|
|
|
|
|
|
A number of stakeholders are daring to do the right thing
|
|
|
|
|
|
|
|
|
|
Prescrire challenges the EMA's secrecy
|
|
|
|
|
|
|
|
|
|